CYP19A1 and prostate cancer: To further complicate the role of testosterone, in situ production of estrogens due to aberrant expression of aromatase in prostate cancer (added to the aromatase already expressed in the adipose tissue), could modify the ratio between circulating and intraprostatic estradiol/testosterone [166].